Company: OFIX
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026066
Chunk: 257

Company: Orthofix Medical Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1B
Chunk 257
---

        $
        30.84

        3.32

       A summary of the status of the Company’s market-based stock option plans as of December 31, 2024, and 2023, and changes during the year ended December 31, 2024, is presented below:

        (In thousands)
         
        Options

        WeightedAverageExercisePrice

        WeightedAverageRemainingContractualTerm (Years)

        Outstanding at December 31, 2023

        —

        —

        Granted

        754

        $
        13.39

        Exercised

        —

        —

        Forfeited or expired

        —

        —

        Outstanding at December 31, 2024

        754

        $
        13.39

        6.19

        Vested and expected to vest at December 31, 2024

        754

        $
        13.39

        6.19

        Exercisable at December 31, 2024

        —

        —

        —

       As of December 31, 2024, the unamortized compensation expense relating to options granted and expected to be recognized was $5.3 million. This amount is expected to be recognized through December 2027 over a weighted average period of approximately 1.1 years. The total intrinsic value of options exercised was less than $0.1 million, $0.0 million, and $0.0 million for the years ended December 31, 2024, 2023, and 2022, respectively. For the year ended December 31, 2024, the Company received $0.2 million cash from stock option exercises, and realized $0.1 million in tax benefit for the tax deductions from stock option exercises. The aggregate intrinsic value of options outstanding and options exercisable as of December 31, 2024, is calculated as the difference between the exercise price of the underlying options and the market price of the Company’s common stock for options that had exercise prices lower than $17.46, the closing price of the Company’s stock on December 31, 2024. The aggregate intrinsic value of options outstanding was $6.9 million as of December 31, 2024. The aggregate intrinsic value of options exercisable was $0.7 million as of that date.Time-based Restricted Stock Awards and Stock UnitsCompensation expense for time-based restricted stock awards